[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-stage4\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-stage4":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634810","feasibility-safety-and-efficacy-of-a-predominantly-plant-based-diet-in-an-asian-population-with-chronic-kidney-disease-100634810",false,"NCT07544524","Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease","Inclusion Criteria:\n\n1. Age 21-79 (Only adults who can give consent will be recruited. Older adults aged 80 are not included to reduce the risk of confounding due to age-related frailty, sarcopenia and multimorbidity. Additionally, older adults may have different nutritional needs and energy requirements)\n2. CKD stage 3-4 (baseline eGFR 15-60ml\u002Fmin\u002F1.72m2 for the past 6 months)\n3. Willingness to see a dietitian and follow either a standard CKD diet or a predominantly plant-based CKD diet\n4. On maximum tolerated dose of ACE-inhibitors (Angiotensin converting enzyme inhibitors) or ARB (Aldosterone receptor blocker) as determined by Renal Physician in charge\n5. Able to provide informed consent\n\nExclusion Criteria:\n\n* Transplant patients (who will tend to have more variable trajectories, immunosuppression related challenges etc which may make this study less feasible)\n* Pregnant or lactating patients (who have different nutritional requirements than the standard CKD patients)\n* Patients who were on any special diet for at least 1 month prior to recruitment (inclusive of\n* long-term vegans or vegetarians) - excluded because they already have stable dietary habits\n* Age \\\u003C21 or \\>\u002F= 80 (Avoid growing children who have different nutritional requirements and advanced elderly who are more likely to have malnutrition or sarcopenia due to other pre-existing causes)\n* Those who have seen a dietitian for CKD previously\n* Patients with severe ischemic heart disease, decompensated liver cirrhosis, malabsorptive diseases or malignancy\n* Patients with BMI \\\u003C18.5 or \\>40\n* Patients with glomerulonephritis, genetic kidney disease or polycystic kidney disease\n* Baseline serum potassium 5.0 and above\n* Patients who are unable to modify their diet due to socio-economic issues.\n* Exclude patients with acute kidney injury (AKI) in the past 6 months prior to study (unstable renal disease","ALL","21 Years","79 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis.\n\nOther exploratory outcomes will include (1) preliminary efficacy of plant-based diets on CKD progression (measured by eGFR decline); (2) risk of nutritional deficiencies such as vitamin D, B12 and iron; and (3) impact on other biochemical parameters of CKD.",[26,27,28],"Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Diet Habit","RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-22","ACTUAL",{"date":35,"type":20},"2026-04-01",{"date":37,"type":20},"2027-09-30",{"name":39,"class":40},"Changi General Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":41},"100616706","clinical-morphometric-and-biochemical-effects-on-adiposopathy-associated-with-the-use-of-glp-1ra-in-ckd-100616706","NCT07309094","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease","ADIPO-CKD","Inclusion Criteria:\n\n* \\> or = 18 years of age\n* diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis\n* had uncontrolled T2DM, CVDs and\u002For obesity\n* willing to participate in the study and sign informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* pregnancy\n* CKD in stage G5 or G4 candidate for dialysis\n* neuropsychiatric diseases preventing the patient from understanding the benefits\u002Frisks associated with the project\n* refusal to participate and\u002For consent revocation were considered as exclusion criteria","18 Years","90 Years",{"count":53,"type":20},250,"OBSERVATIONAL","Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue.\n\nThe aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.",[26,27,57,58,59,60],"Chronic Kidney Disease Stage 1","Chronic Kidney Disease Stage 2","Obesity","Diabetes Mellitus, Type 2",[62,63,64,65,66,67,68],"chronic kidney disease","type 2 diabetes mellitus","GLP-1RA","adiposopathy","perivisceral adipose tissue","perirenal adipose tissue","inflammation","2025-12-15",{"date":71,"type":33},"2025-12-30",{"date":73,"type":33},"2023-09-15",{"date":75,"type":20},"2028-12-31",{"name":77,"class":40},"Cardenal Herrera University",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100476836","low-protein-diet-with-low-protein-foods-versus-a-lpd-without-lp-foods-in-patients-with-chronic-kidney-disease-ckd-100476836","NCT05489120","Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)","Randomized Controlled Trial of a Low-Protein Diet (LPD) With Low-Protein (LP) Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD): Efficacy and Feasibility Study","Inclusion Criteria:\n\n* CKD patient stage 3a-5 (\\\u003C60 ml\u002Fmin\u002F1.73 m² estimated by CKD-EPI formula) and not on dialysis,\n* With a good nutritional status (i.e., absence of malnutrition according to albumin, pre-albumine, BMI and no clinical and paraclinical criteria of malnutrition),\n* Above 1g protein\u002F kg bw (ideal body weight),\n* LPD-naïve patient,\n* Motivated to LPD introduction (ensure during screening phase patient willingness to modify diet habits with counselling accurate follow-up),\n* Available to attend the visits planned by the protocol and able to complete the data collection documents (diet record and self-administered questionnaires),\n* Subject affiliated to a health insurance system or is a beneficiary (art. L.1121-11, Code of Public Health, France),\n* Having given their informed written consent regarding its participation to the protocol.\n\nExclusion Criteria:\n\n* Patient for whom dialysis or transplantation is planned\u002Fexpected within the next 12 months\n* Known allergic reactions to the ingredients present in FLAVIS products (milk, eggs, soy, nut),\n* Uncontrolled Diabetes (HbA1C \\>8.5%),\n* Active cancer (including a 5 years remission period),\n* Psychiatric disorders or inability to follow the protocol,\n* Evidence of any active infectious or uncontrolled inflammatory diseases,\n* Inability to provide blood samples (poor venous capital),\n* Inability to perform correct 24-hours urine collection,\n* Any change of the chronic medication within 1 month before screening,\n* Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and\u002For the participation of the subject in the study according to the opinion of the investigator,\n* Patient with an active implanted medical device\n* Simultaneous participation in another clinical trial or subject still within the exclusion period of a previous clinical trial.\n* Vulnerable subjects (art. L. 1121-5 à 8 et L. 1122-1-2, Code of Public Health, France) are also excluded from the clinical trial.",{"count":86,"type":20},244,[23],"The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease\u002Fdeath and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein\u002F kg body weight\u002Fday is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.",[90,27,91,92],"Chronic Kidney Disease Stage 3B","Chronic Kidney Disease Stage 5","Chronic Kidney Disease Stage 3A",[94,95,96,97,98,99],"low-protein diet","low-protein foods","FLAVIS","compliance","effectiveness","safety","2025-01-27",{"date":102,"type":33},"2025-01-29",{"date":104,"type":33},"2022-11-06",{"date":106,"type":20},"2026-03",{"name":108,"class":109},"Dr. Schär AG \u002F SPA","INDUSTRY",21]